CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced it will present at each of the following upcoming healthcare conferences:
- The 38th Annual Cowen & Co. Health Care Conference: a corporate overview will be presented on Wednesday, March 14 at 10:40 a.m. ET in Boston, MA.
- Oppenheimer's 28th Annual Healthcare Conference: a corporate overview will be presented on Tuesday, March 20 at 10:20 a.m. ET in New York, NY.
A live audio webcast of each presentation will be available under the “Investors and Media” section of Seres’ website. A replay of each presentation will become available approximately one hour after the event and will be archived for 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc., is a
leading microbiome therapeutics platform company developing a novel
class of biological drugs that are designed to treat disease by
restoring the function of a dysbiotic microbiome, where the natural
state of bacterial diversity and function is imbalanced. Seres’ lead
program, SER-109, has obtained Breakthrough Therapy and Orphan Drug
designations from the U.S. Food and Drug Administration and is in Phase
3 development for multiply recurrent C. difficile infection.
Seres’ clinical candidate SER-287 has successfully completed a Phase 1b
study in patients with mild-to-moderate Ulcerative Colitis and has
obtained Orphan Drug designation for pediatric Ulcerative Colitis. Seres
is also developing SER-262, the first ever synthetic microbiome
therapeutic candidate, in a Phase 1b study in patients with primary C.
difficile infection and is developing SER-401 to enhance the
efficacy of checkpoint inhibitors in patients with certain tumors. For
more information, please visit www.serestherapeutics.com.
Follow us on Twitter @SeresTx.
